GO:0009000 selenocysteine lyase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0009000 selenocysteine lyase activity catalyzes the reaction L-selenocysteine + reduced acceptor = hydrogen selenide + L-alanine + acceptor.
• The enzyme is also known as selenocysteine beta-lyase and is widely distributed in bacteria, archaea, and mammals.
• It provides a selenium recycling route that liberates hydrogen selenide for selenoprotein biosynthesis.
• Global loss of selenocysteine lyase in mice causes lipid accumulation in brown adipocytes and cardiac redox imbalance.
• Enzymological characterization has been achieved for bacterial enzymes such as Leuconostoc mesenteroides selenocysteine beta-lyase.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of selenocysteine lyase function in disease.
Description
Selenocysteine lyase activity (GO:0009000) is a molecular function that decomposes the selenium-containing amino acid L-selenocysteine into L-alanine and hydrogen selenide, using a reduced acceptor. This reaction is central to selenium recycling because it releases selenium in a form that can be reincorporated into newly synthesized selenoproteins. The enzyme is conserved from bacteria to mammals and is often called selenocysteine beta-lyase. Researchers study GO:0009000 to understand how cells manage selenium homeostasis, redox balance, and the supply of selenocysteine for selenoprotein synthesis. Because selenium is both essential and toxic, the lyase sits at a critical metabolic junction, and its dysfunction has been linked to metabolic and cardiovascular phenotypes in mouse models. The activity also modulates drug toxicity in renal cells, as shown for selenocysteine Se-conjugates. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of GO:0009000, its genes, mechanisms, disease relevance, and experimental approaches.
selenocysteine lyase activity At A Glance
| GO ID | GO:0009000 |
|---|---|
| GO term | selenocysteine lyase activity |
| Ontology | molecular_function |
| Synonym | L-selenocysteine selenide-lyase (L-alanine-forming); selenocysteine beta-lyase activity; selenocysteine reductase activity |
| Major function | Catalyzes decomposition of L-selenocysteine to hydrogen selenide and L-alanine using a reduced acceptor |
| Reaction | L-selenocysteine + reduced acceptor = hydrogen selenide + L-alanine + acceptor |
| Cofactor | Pyridoxal 5'-phosphate (PLP) in characterized bacterial and mammalian enzymes |
| Distribution | Bacteria, archaea, and mammals; first enzymological characterization in Leuconostoc mesenteroides |
| Physiological role | Selenium recycling for selenoprotein biosynthesis and redox homeostasis |
What Is GO:0009000?
GO:0009000 selenocysteine lyase activity is defined as catalysis of the reaction L-selenocysteine + reduced acceptor = hydrogen selenide + L-alanine + acceptor. In other words, the enzyme removes selenium from selenocysteine, transferring it to a reduced acceptor and releasing hydrogen selenide, while the carbon skeleton becomes alanine. This is a pyridoxal 5'-phosphate-dependent beta-elimination reaction in many characterized enzymes. The activity is synonymous with selenocysteine beta-lyase, selenocysteine reductase, and L-selenocysteine selenide-lyase (L-alanine-forming).
Why Is selenocysteine lyase activity Important in Cell Biology?
GO:0009000 is important because it controls the intracellular supply of selenium for selenoprotein synthesis and protects cells from selenium toxicity by converting selenocysteine into a reusable form. Disruption of selenocysteine lyase in mice leads to lipid accumulation in brown adipocytes and cardiac redox imbalance, indicating that this activity is required for metabolic and cardiovascular homeostasis. The enzyme also modulates the toxicity of selenium-containing drugs such as selenocysteine Se-conjugates in renal tubular cells. Therefore, GO:0009000 is a key node linking selenium metabolism, redox biology, and disease.
• Provides a selenium recycling pathway for selenoprotein biosynthesis.
• Prevents accumulation of toxic selenocysteine by converting it to hydrogen selenide and alanine.
• Supports brown adipocyte lipid homeostasis, as shown by global loss-of-function in mice.
• Maintains cardiac redox balance; disruption causes cardiac redox imbalance in mice.
• Modulates cisplatin-mediated toxicity in renal tubular cells via beta-lyase-dependent mechanisms.
• Is conserved across microbes and mammals, enabling comparative enzymology.
• Represents a target for understanding selenium-related metabolic disorders.
• Can be studied with CRISPR models to establish causal roles in disease.
• Influences ferroptosis pathways through selenium recycling, as shown in renal ischemia-reperfusion injury.
• Has potential therapeutic implications for conditions involving selenium dyshomeostasis.
Mechanism, Genes and Research Methods of selenocysteine lyase activity
Substrate recognition and binding
In simple terms: The enzyme grabs selenocysteine and holds it in place for chemical breakdown.
Selenocysteine lyase binds L-selenocysteine as its primary substrate, distinguishing it from L-cysteine. The enzyme uses a reduced acceptor to accept the selenium atom during catalysis. In characterized bacterial enzymes such as Leuconostoc mesenteroides selenocysteine beta-lyase, substrate specificity and kinetic parameters have been determined. The reaction is a beta-elimination that releases hydrogen selenide and L-alanine.
Catalytic mechanism and cofactor requirement
In simple terms: A helper molecule called PLP helps the enzyme break selenocysteine apart.
Selenocysteine lyase activity is pyridoxal 5'-phosphate (PLP)-dependent in many enzymes, forming a Schiff base with the substrate to facilitate beta-elimination. The catalytic cycle converts L-selenocysteine and a reduced acceptor into hydrogen selenide, L-alanine, and an oxidized acceptor. The first enzymological characterization of a lactic acid bacterium enzyme confirmed PLP dependence and provided kinetic constants. This mechanism is distinct from that of cysteine desulfurases, although some structural similarities exist.
Selenium recycling and selenoprotein synthesis
In simple terms: The selenium freed from selenocysteine is reused to build new selenoproteins.
The hydrogen selenide produced by GO:0009000 can be used for selenophosphate synthesis, which is required for selenocysteine incorporation into selenoproteins. This recycling pathway is essential when selenium is limiting, allowing cells to reuse selenium from degraded selenoproteins. In renal ischemia-reperfusion injury, promoting selenium recycling via rhBNP inhibited ferroptosis, highlighting the physiological importance of this pathway. Thus, selenocysteine lyase activity is a central node in selenium economy.
Regulation of selenocysteine lyase expression and activity
In simple terms: Cells adjust how much of this enzyme they make based on selenium levels and stress.
Selenocysteine lyase expression is regulated in response to selenium status and oxidative stress, although the exact mechanisms vary by tissue. In mice, global loss of selenocysteine lyase leads to tissue-specific phenotypes such as lipid accumulation in brown adipocytes and cardiac redox imbalance, indicating that regulation is critical for metabolic and cardiac function. The enzyme's activity can also be modulated by its substrate availability and by the redox state of the cell. Further studies are needed to fully define transcriptional and post-translational regulation.
Microbial distribution and diversity
In simple terms: Many different bacteria make this enzyme, but not all of them.
Microbial distribution studies show that selenocysteine lyase activity is present in a range of bacteria, including Escherichia coli and Leuconostoc mesenteroides. A cysteine-requiring mutant of E. coli K-12 was used to detect selenocysteine lyase activity, demonstrating its presence in this organism. The enzyme is not universal, as some microbes lack detectable activity. This diversity makes microbial systems useful for comparative enzymology.
Key Genes Involved in GO:0009000 selenocysteine lyase activity
The following genes and proteins are directly implicated in selenocysteine lyase activity (GO:0009000) or its physiological context, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SCLY (mammalian selenocysteine lyase) | Catalyzes decomposition of selenocysteine to hydrogen selenide and alanine | Global knockout in mice causes lipid accumulation in brown adipocytes and cardiac redox imbalance |
| Escherichia coli selenocysteine lyase | Microbial enzyme with selenocysteine lyase activity | Detected in cysteine-requiring mutant; used for microbial distribution studies |
| Leuconostoc mesenteroides selenocysteine beta-lyase | First enzymologically characterized lactic acid bacterium enzyme | Provides kinetic and cofactor data for GO:0009000 |
| Selenophosphate synthetase (SEPHS) | Uses hydrogen selenide for selenophosphate synthesis | Links GO:0009000 to selenoprotein biosynthesis |
| Selenocysteine synthase (SEPSECS) | Incorporates selenocysteine into selenoproteins | Downstream of selenium recycling |
| Selenoprotein P (SELENOP) | Selenium transport protein | Affects selenium availability for recycling |
| Glutathione peroxidase (GPX) | Selenoprotein antioxidant enzyme | Redox balance influenced by selenium recycling |
| Thioredoxin reductase (TXNRD) | Selenoprotein oxidoreductase | Redox homeostasis linked to selenocysteine metabolism |
| Cysteine desulfurase (NFS1) | Related PLP-dependent enzyme | Comparative mechanism studies |
| Ferroptosis regulators (GPX4) | Lipid peroxidation defense | Selenium recycling via GO:0009000 affects ferroptosis |
| rhBNP (recombinant human BNP) | Promotes selenium recycling | Inhibited ferroptosis in renal ischemia-reperfusion injury |
| Cisplatin | Nephrotoxic drug | Selenocysteine Se-conjugates attenuate toxicity via beta-lyase |
| Selenocysteine Se-conjugates | Prodrugs activated by beta-lyase | Modulate cisplatin toxicity in renal tubular cells |
| PLP (pyridoxal 5'-phosphate) | Cofactor for beta-elimination | Required for catalytic activity |
| Reduced acceptor (e.g., DTT, thioredoxin) | Electron donor in the reaction | Essential for turnover |
| SCLY knockout mouse | Model for loss of function | Shows metabolic and cardiac phenotypes |
| Brown adipocytes | Cell type affected by SCLY loss | Lipid accumulation phenotype |
| Cardiomyocytes | Cell type affected by SCLY loss | Cardiac redox imbalance phenotype |
How Is selenocysteine lyase activity Regulated?
Selenocysteine lyase activity is regulated at multiple levels. Expression of the mammalian SCLY gene responds to selenium status and oxidative stress, although precise transcriptional mechanisms remain incompletely defined. The enzyme's activity depends on PLP availability and the redox state of the cell, which affects the reduced acceptor pool. In mice, global loss of SCLY leads to tissue-specific phenotypes, indicating that regulation is critical for metabolic and cardiac homeostasis. Additionally, selenium recycling via GO:0009000 can be promoted by factors such as rhBNP, which inhibits ferroptosis in renal ischemia-reperfusion injury. These layers of regulation ensure that selenium is available for selenoprotein synthesis while avoiding toxicity.
selenocysteine lyase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SCLY | Brown adipocyte lipid accumulation | Global knockout mouse |
| SCLY | Cardiac redox imbalance | Cardiac-specific knockout mouse |
| SCLY / GPX4 | Ferroptosis in renal ischemia-reperfusion injury | Renal ischemia-reperfusion mouse model with rhBNP treatment |
| SCLY / beta-lyase | Cisplatin nephrotoxicity | Renal tubular cell lines with selenocysteine Se-conjugates |
| SCLY | Selenium metabolism disorders | Cell models with SCLY knockout or overexpression |
Metabolic disorders and brown adipocyte lipid accumulation
Global loss of selenocysteine lyase in mice drives lipid accumulation in brown adipocytes, suggesting that GO:0009000 is required for normal lipid metabolism in thermogenic adipose tissue. This phenotype links selenocysteine catabolism to energy balance and metabolic disease. The mechanism may involve altered selenium availability for selenoproteins that regulate redox and lipid handling.
Cardiac redox imbalance and cardiovascular disease
Disruption of selenocysteine decomposition in mice causes cardiac redox imbalance, indicating that GO:0009000 protects the heart from oxidative stress. This finding suggests that selenocysteine lyase dysfunction may contribute to cardiomyopathy or heart failure under stress conditions. The cardiac phenotype underscores the importance of selenium recycling for antioxidant defense.
Renal ischemia-reperfusion injury and ferroptosis
In renal ischemia-reperfusion injury, rhBNP inhibited ferroptosis by promoting selenium recycling, a pathway that depends on selenocysteine lyase activity. This links GO:0009000 to cell death mechanisms and kidney injury. The study highlights the therapeutic potential of enhancing selenium recycling to prevent ferroptotic damage.
Chemotherapy toxicity and renal tubular cells
Beta-lyase-dependent attenuation of cisplatin-mediated toxicity by selenocysteine Se-conjugates has been demonstrated in renal tubular cell lines. This suggests that selenocysteine lyase activity can modulate drug toxicity and may be exploited to reduce nephrotoxicity. The findings connect GO:0009000 to pharmacological interventions.
From selenocysteine lyase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SCLY loss cause lipid accumulation in brown adipocytes? | Global SCLY knockout mouse |
| Does SCLY loss cause cardiac redox imbalance? | Cardiac-specific SCLY knockout mouse |
| Can selenium recycling inhibit ferroptosis in kidney injury? | Renal ischemia-reperfusion model with rhBNP |
| Does beta-lyase activity modulate cisplatin toxicity? | Renal tubular cell lines with selenocysteine Se-conjugates |
| What is the kinetic mechanism of bacterial selenocysteine lyase? | Recombinant Leuconostoc mesenteroides enzyme |
| Is SCLY activity detectable in E. coli mutants? | Cysteine-requiring E. coli K-12 mutant |
How to Study the selenocysteine lyase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Hydrogen selenide release assay | Selenocysteine lyase activity | Kinetic characterization of recombinant enzyme |
| Alanine formation assay | Beta-elimination product | Confirmation of GO:0009000 |
| CRISPR knockout followed by lipid staining | Lipid accumulation in brown adipocytes | Metabolic phenotyping |
| Redox balance assays (GSH/GSSG, ROS) | Cardiac redox state | Cardiac phenotyping |
| Ferroptosis markers (lipid peroxidation, GPX4) | Cell death pathway | Renal ischemia-reperfusion injury |
| Cisplatin toxicity assays | Cell viability | Renal tubular cell lines |
| Microbial growth assays | Selenocysteine lyase presence | Bacterial distribution studies |
| Enzyme kinetics (Km, kcat) | Catalytic efficiency | Enzymological characterization |
Enzymatic activity assays
Selenocysteine lyase activity can be measured by monitoring the release of hydrogen selenide or alanine from L-selenocysteine in the presence of a reduced acceptor. These assays are used to characterize kinetic parameters and cofactor requirements. They are essential for confirming GO:0009000 in cell lysates or recombinant preparations.
Genetic knockout and phenotypic analysis
CRISPR knockout of SCLY in mice or cell lines allows assessment of loss-of-function phenotypes such as lipid accumulation in brown adipocytes or cardiac redox imbalance. These models are used to establish causal roles of GO:0009000 in metabolism and cardiovascular function. Phenotypic readouts include lipid staining, redox measurements, and gene expression profiling.
Selenium recycling and ferroptosis assays
Selenium recycling can be assessed by measuring selenoprotein levels or ferroptosis markers after modulating GO:0009000. In renal ischemia-reperfusion injury, rhBNP treatment promoted selenium recycling and inhibited ferroptosis. These assays link enzyme activity to cell death pathways.
Microbial distribution and comparative genomics
Microbial distribution studies use enzymatic assays and genomic analysis to identify organisms with selenocysteine lyase activity. The cysteine-requiring E. coli mutant is a classic tool for detecting activity. Comparative enzymology with Leuconostoc mesenteroides provides insights into conserved mechanisms.
How CRISPR Can Be Used to Study GO:0009000 selenocysteine lyase activity
Knockout
CRISPR knockout of SCLY in mice or cell lines is used to study loss of selenocysteine lyase activity. Global knockout in mice causes lipid accumulation in brown adipocytes and cardiac redox imbalance. These models establish causal roles for GO:0009000 in metabolism and cardiovascular function.
Point Mutation
Point mutations can be introduced into the SCLY catalytic site to dissect residues required for PLP binding or substrate recognition. Such mutants help distinguish catalytic activity from structural roles. They are valuable for understanding the mechanism of GO:0009000.
Knock-in
Knock-in of tagged SCLY (e.g., FLAG or GFP) allows localization and interaction studies. Knock-in of disease-associated variants can model human phenotypes. These models are useful for tracking endogenous enzyme dynamics.
Overexpression
Overexpression of SCLY in cell lines can enhance selenium recycling and protect against ferroptosis or oxidative stress. It is used to test sufficiency of GO:0009000 in rescue experiments. Overexpression models also help study substrate flux and product formation.
How EDITGENE Supports selenocysteine lyase activity Research
Researchers studying selenocysteine lyase activity-related genes often need to determine whether a candidate gene is causally involved in selenium metabolism, redox balance, or disease phenotypes. EDITGENE provides CRISPR-based cell models and screening services to enable such causal studies with high precision.
Contact EDITGENE today to design your custom CRISPR model for selenocysteine lyase activity research.
Frequently Asked Questions About selenocysteine lyase activity
What is selenocysteine lyase activity?
Selenocysteine lyase activity (GO:0009000) is a molecular function that catalyzes the reaction L-selenocysteine + reduced acceptor = hydrogen selenide + L-alanine + acceptor.
What genes are involved in selenocysteine lyase activity?
The main gene is SCLY, encoding selenocysteine lyase; microbial enzymes are found in Escherichia coli and Leuconostoc mesenteroides.
What is the GO ID for selenocysteine lyase activity?
The Gene Ontology ID is GO:0009000.
What is another name for selenocysteine lyase activity?
It is also called selenocysteine beta-lyase, selenocysteine reductase, or L-selenocysteine selenide-lyase (L-alanine-forming).
What reaction does selenocysteine lyase catalyze?
It converts L-selenocysteine and a reduced acceptor into hydrogen selenide, L-alanine, and an oxidized acceptor.
Why is selenocysteine lyase important for selenium metabolism?
It recycles selenium from selenocysteine into hydrogen selenide for selenoprotein synthesis and prevents selenium toxicity.
What happens when selenocysteine lyase is knocked out in mice?
Global loss causes lipid accumulation in brown adipocytes and cardiac redox imbalance.
Is selenocysteine lyase involved in ferroptosis?
Yes, promoting selenium recycling via this pathway inhibited ferroptosis in renal ischemia-reperfusion injury.
How can I study selenocysteine lyase activity in the lab?
Enzymatic assays, CRISPR knockout models, and selenium recycling assays are commonly used.
Does selenocysteine lyase affect drug toxicity?
Beta-lyase-dependent attenuation of cisplatin toxicity by selenocysteine Se-conjugates has been shown in renal tubular cells.
Conclusion
GO:0009000 selenocysteine lyase activity is a conserved molecular function that decomposes selenocysteine to recycle selenium and maintain redox homeostasis. Its physiological importance is underscored by mouse models where loss causes metabolic and cardiac phenotypes, and by its role in ferroptosis and drug toxicity. Studying this activity with CRISPR-based models and biochemical assays will continue to reveal how selenium metabolism intersects with human disease.
References
- 1. Karle JA et al.. 1986. Selenocysteine lyase activity in a cysteine-requiring mutant ofEscherichia coli K-12.. Biol Trace Elem Res 10(4):307-15 PMID: 24254436
- 2. Chocat P et al.. 1983. Microbial distribution of selenocysteine lyase.. J Bacteriol 156(1):455-7 PMID: 6225771
- 3. Seale LA. 2019. Selenocysteine β-Lyase: Biochemistry, Regulation and Physiological Role of the Selenocysteine Decomposition Enzyme.. Antioxidants (Basel) 8(9) PMID: 31480609
- 4. Shimada BK et al.. 2026. Global loss of selenocysteine lyase in mice drives lipid accumulation in brown adipocytes.. Am J Physiol Endocrinol Metab 330(2):E000 PMID: 41452587
- 5. Shimada BK et al.. 2025. Cardiac redox imbalance upon disruption of selenocysteine decomposition in mice.. Am J Physiol Heart Circ Physiol 329(6):H1480-H1496 PMID: 41134664
- 6. Huang M et al.. 2026. rhBNP inhibited ferroptosis in renal ischemia-reperfusion injury through promoting selenium recycling.. Free Radic Biol Med 245:283-300 PMID: 41482081
- 7. Oikawa T et al.. 2022. First enzymological characterization of selenocysteine β-lyase from a lactic acid bacterium, Leuconostoc mesenteroides.. Amino Acids 54(5):787-798 PMID: 35122135
- 8. Rooseboom M et al.. 2002. Beta-lyase-dependent attenuation of cisplatin-mediated toxicity by selenocysteine Se-conjugates in renal tubular cell lines.. J Pharmacol Exp Ther 301(3):884-92 PMID: 12023515
